CG Results offers the skills of an experienced and entrepreneurial healthcare team dedicated to the life sciences sector having closed more than 75 successful transactions to date. Our clients trust us because of our strong international relationships with shareholders and management teams across the healthcare lifecycle. We combine expert financial capabilities with backgrounds in science, healthcare and IT that will bring value to your business.
We work with businesses and entrepreneurs to help articulate the ideal equity story, target the right investors and negotiate the best deal.
• Full service offering for Healthcare M&A transactions, for both buyers and sellers
• Advice on strategic options for healthcare businesses and assets
• Expert guidance on development capital, utilisation of investments or finance for MBO/MBI
• Support for licensing transactions for research assets and marketed products
Our highly specialised, global team works together seamlessly across six focus areas in the healthcare sector.
Pharma Commercialisation Services Update – February 2023
Welcome to our latest update on the outsourced Pharma Commercialisation Services sector. In this report we will be reviewing deal activity across 2022 and taking a look forward to see what 2023 may hold for the sector. We hope that you enjoy this report and look forward to discussing the data and underlying themes with […]
Pharma Licensing – an introduction
We are pleased to share our introduction to Pharma Licensing. This guide provides an overview of both in and out-licensing as well as insights on what to anticipate during the process. We hope that you find this guide useful and look forward to discussing the underlying themes with you. Do get in touch! Click to […]
Pharma Licensing: the why the how and a few things to get right
Platform or asset licensing has increasingly been utilised across the bio-pharmaceutical industry to achieve Corporate objectives by sharing intellectual property (IP). IP includes patents and know-how and third-party proprietary technologies, compounds and products, and can be used to build on existing therapeutic areas, expand into different geographies or to diversify portfolios. A pharma licensing deal […]